cytochrome P450 family 26 subfamily B member 1Genealiases: CYP26A2 · P450RAI-2 · P450RAI2 · RHFCA
Q-omics provides the consensus-scored CYP26B1 profile across patient tissues and cancer cell-line models. CYP26B1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, CYP26B1 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, CYP26B1 RNA expression shows 17,980 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight ACC, HNSC, and DLBC as cancer lineages where CYP26B1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CYP26B1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CYP26B1 survival associations across molecular data types. CYP26B1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (11) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CYP26B1 RNA expression–survival associations across cancer types. High CYP26B1 expression shows unfavorable associations in ACC, LIHC and UCEC, but favorable associations in SCLC, DLBC and THCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for CYP26B1 RNA expression.
This table summarizes CYP26B1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 3. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for CYP26B1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CYP26B1 shows lower tumor expression in THCA, KIRC, KICH, COAD and BRCA and higher tumor expression in HNSC. The HNSC box plot shows higher CYP26B1 RNA expression in tumor versus normal tissue (log2 FC = +2.007, t-test p < 0.001).
This table shows molecular features associated with CYP26B1 in patient tissues and cancer cell lines. In patient samples, CYP26B1 shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set. In cancer cell lines, CYP26B1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and LARGE_INTESTINE.
